Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 3 for:    rodatristat ethyl | Recruiting, Not yet recruiting Studies | Pulmonary Arterial Hypertension

Multiple-Ascending Dose in Japanese Patients Bridging Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05065359
Recruitment Status : Recruiting
First Posted : October 4, 2021
Last Update Posted : January 18, 2022
Sponsor:
Collaborators:
Altavant Sciences, Inc.
Parexel
Information provided by (Responsible Party):
Altavant Sciences GmbH

Tracking Information
First Submitted Date  ICMJE August 2, 2021
First Posted Date  ICMJE October 4, 2021
Last Update Posted Date January 18, 2022
Actual Study Start Date  ICMJE October 1, 2021
Estimated Primary Completion Date March 31, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 22, 2021)
Safety of rodatristat ethyl by incidence of adverse events [ Time Frame: 21 days ]
Assessments of adverse events
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 22, 2021)
  • Single dose AUC(0-∞) [ Time Frame: 21 days ]
    Single dose area under the concentration time curve from time zero (predose-) extrapolated to infinity (AUC(0-∞)) of rodatristat ethyl and metabolite(s).
  • Single dose AUC(0-t) [ Time Frame: 21 days ]
    Single dose area under the concentration time curve from time zero to the last detectable time point (AUC(0-t)) of rodatristat ethyl and metabolite(s).
  • Single dose Cmax [ Time Frame: 21 days ]
    Single dose maximum observed concentration (Cmax) of rodatristat ethyl and metabolite(s).
  • Single dose tmax [ Time Frame: 21 days ]
    Single dose time to maximum concentration (tmax) of rodatristat ethyl and metabolite(s).
  • Single dose t½ [ Time Frame: 21 days ]
    Single dose elimination half-life (t½) of rodatristat ethyl and metabolite(s).
  • Steady state tmax [ Time Frame: 21 days ]
    Steady-state tmax of rodatristat ethyl and metabolite(s).
  • Steady state Cmax [ Time Frame: 21 days ]
    Steady-state Cmax of rodatristat ethyl and metabolite(s).
  • Steady state Cτ [ Time Frame: 21 days ]
    Steady-state concentration at end of dosing interval (Cτ) of rodatristat ethyl and metabolite(s).
  • Steady state Cavg [ Time Frame: 21 days ]
    Steady-state average concentration at steady state (Cavg) of rodatristat ethyl and metabolite(s).
  • Steady state AUC(0-τ) [ Time Frame: 21 days ]
    Steady-state area under the concentration-time curve over the dosing interval at steady-state (AUC(0-τ)) of rodatristat ethyl and metabolite(s).
  • Steady state t½ [ Time Frame: 21 days ]
    Steady-state t½ of rodatristat ethyl and metabolite(s).
  • Pharmacodynamic assessment - change from baseline in 5-HIAA concentrations [ Time Frame: 21 days ]
    PD as assessed by the change from baseline in 5-hydroxyindoleacedtic acid (5-HIAA) concentrations (plasma and 24-hour urinary excretion)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Multiple-Ascending Dose in Japanese Patients Bridging Study
Official Title  ICMJE A Randomized, Double-Blinded, Placebo-Controlled, MultipleAscending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rodatristat Ethyl in Healthy Japanese and Caucasian Subjects
Brief Summary This study is a randomized, placebo-controlled, multiple-ascending dose study in healthy Japanese and Caucasian subjects.
Detailed Description This study is a randomized, placebo-controlled, multiple-ascending dose study in healthy Japanese and Caucasian subjects. Two dose levels of rodatristat ethyl, 300 mg twice daily (BID) and 600 mg BID multiple doses (with a single dose lead in), will be explored in an ascending dose fashion with a safety review in between (Figure 1 below). Approximately 48 subjects will be enrolled in 4 cohorts.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Multiple Ascending Dose
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: Rodatristat Ethyl 300 mg BID
    Tablets, oral, 300 mg, BID 14 days
  • Drug: Rodatristat Ethyl 600 mg BID
    Tablets, oral, 600 mg, BID 14 days
  • Drug: Placebo
    Tablets, oral, 0 mg, BID for 14 days
Study Arms  ICMJE
  • Experimental: Rodatristat Ethyl 300 mg BID - Japanese subjects
    Intervention: Drug: Rodatristat Ethyl 300 mg BID
  • Placebo Comparator: Placebo match for Rodatristat Ethyl 300 mg BID - Japanese subjects
    Intervention: Drug: Placebo
  • Experimental: Rodatristat Ethyl 300 mg BID - Caucasian subjects
    Intervention: Drug: Rodatristat Ethyl 300 mg BID
  • Placebo Comparator: Placebo match for Rodatristat Ethyl 300 mg BID - Caucasian subjects
    Intervention: Drug: Placebo
  • Experimental: Rodatristat Ethyl 600 mg BID - Japanese subjects
    Intervention: Drug: Rodatristat Ethyl 600 mg BID
  • Placebo Comparator: Placebo match for Rodatristat Ethyl 600 mg BID - Japanese subjects
    Intervention: Drug: Placebo
  • Experimental: Rodatristat Ethyl 600 mg BID - Caucasian subjects
    Intervention: Drug: Rodatristat Ethyl 600 mg BID
  • Placebo Comparator: Placebo match for Rodatristat Ethyl 600 mg BID - Caucasian subjects
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 22, 2021)
48
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 31, 2022
Estimated Primary Completion Date March 31, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy males or females aged 18 to 55 years, inclusive
  • A male subject is eligible to participate if he does not have a female partner who is pregnant or who intends to become pregnant during the study. Male subjects must agree to use contraception starting at Screening, during the treatment period, and for at least 100 days after the last dose of Investigational Product (IP), and refrain from donating sperm during this period.
  • Female subjects of childbearing potential must agree to use contraception starting at Screening, during the treatment period, and for at least 30 days after the last dose of IP.
  • Body mass index (BMI) ≥ 18 kg/m2 and ≤ 32 kg/m2 at Screening
  • Japanese subjects must have been born in Japan and not have lived outside of Japan > 10 years at the time of Screening, have both parents and grandparents of ethnic Japanese origin, and have not significantly modified their diets since leaving Japan.
  • Caucasian subjects must be of European or Latin American descent (i.e., White).
  • Capable of giving signed informed consent, able to understand and comply with protocol requirements, instructions, and protocol related restrictions, and likely to complete the study as planned.

Exclusion Criteria:

  • Any known pre-existing medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings including, but not limited to a history of clinically significant gastrointestinal, hematologic, renal, hepatic, bronchopulmonary, neurological, psychiatric, or cardiovascular disease
  • a. History of Gilbert's Syndrome
  • b. History of depression
  • c. History of any allergy that, in the opinion of the Investigator, contraindicates participation in the trial
  • Any positive finding on the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at Screening) of 50 mL to 499 mL of blood within 30 days or more than 499 mL within 56 days prior to Day 1
  • Participation in an investigational drug, vaccine, or device study within 30 days before IP administration or 90 days for a biologic study
  • Evidence of previous myocardial infarction
  • a. Any conduction abnormality (including but not specific to atrioventricular block [2nd degree or higher], Wolff Parkinson White syndrome [unless curative ablation treatment]).
  • b. Sinus pauses > 3 seconds.
  • c. Any significant arrhythmia which, in the opinion of the Investigator and Medical Monitor, will interfere with the safety for the individual subject.
  • d. Non-sustained or sustained ventricular tachycardia (≥ 3 consecutive ventricular ectopic beats).
  • Abnormal blood pressure, either low (defined as < 90 mmHg systolic and/or < 50 mmHg diastolic) or high (defined as > 140 mmHg systolic and/or > 90 mmHg diastolic)
  • Clinically significant abnormalities in laboratory test results (including hepatic and renal panels, complete blood count, coagulation, chemistry panel, and urinalysis)
  • a. Positive serology for hepatitis B, hepatitis C virus, or human immunodeficiency virus
  • b. Estimated glomerular filtration rate < 80 mL/min/1.73 m2
  • c. Aspartate aminotransferase, alanine aminotransferase values greater than 1.5 x upper limit of normal.
  • d. Positive urine test for drugs of abuse
  • e. Positive alcohol test (breath, saliva, or urine)
  • Use of prescription or nonprescription drugs including high dose vitamins, dietary supplements (including St. John's Wort) within 7 days or 5 half-lives of the prescription or nonprescription drug (whichever was longer) prior to the first dose of IP product, unless in the opinion of the Investigator and Sponsor, the medication would not interfere with the study outcomes or compromise subject safety.
  • Subject unable to abstain from consumption of tryptophan-rich foods 48 hours prior to admission to the clinic through the Follow-up visit
  • Consumption of grapefruit or Seville oranges or their juices within the 7 days prior to dosing until collection of the final PK sample.
  • Use of medications associated with QT prolongation within 30 days prior to dosing and during the study. A list of prohibited medications is provided in an appendix to the protocol.
  • Subjects unable to abstain from alcohol for 72 hours prior to the start of dosing through collection of their final PK sample
  • Subjects with a clinical history of or current alcohol abuse defined as an average weekly intake of more than 21 units for males or 15 units for females (1 unit = 340 mL beer, 115 mL wine, or 43 mL spirits).
  • Subjects with a clinical history of or current illicit drug use which, in the opinion of the Investigator, would interfere with the subject's ability to complete the study and could compromise subject safety and/or the results of the study.
  • Subjects unable to abstain from caffeine, xanthine, or strenuous exercise for 72 hours prior to dosing until collection of their final PK sample.
  • Subjects who have smoked or used tobacco or nicotine-containing products or cannabidiol and related products (in all forms) within 3 months prior to the Screening visit and who are unwilling to refrain from cannabidiol and related products, smoking, tobacco use, or use of nicotine products and all for the entire duration of the study (through the Follow-up visit)
  • History of hypersensitivity to rodatristat ethyl, any its components, or any components in the placebo preparation.
  • Employed as site personnel directly involved with this study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Jill M Denning 919-561-6641 jill.denning@altavant.com
Contact: Howard M Lazarus, MD, FCCP 919-561-6641 howard.lazarus@altavant.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05065359
Other Study ID Numbers  ICMJE RVT-1201-1005
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Altavant Sciences GmbH
Study Sponsor  ICMJE Altavant Sciences GmbH
Collaborators  ICMJE
  • Altavant Sciences, Inc.
  • Parexel
Investigators  ICMJE Not Provided
PRS Account Altavant Sciences GmbH
Verification Date January 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP